Biotech

All Articles

OS Treatments refiles $6M IPO to money HER2 medication, preclinical ADCs

.OS Therapies will certainly list on the NYSE American supply exchange this morning via a $6.4 milli...

ALX's waning CD47 reaction price sends out stock spiraling down

.ALX Oncology's phase 2 stomach cancer cells feedback price has actually deteriorated. After seeing ...

Ionis centers eye health condition from aim ats of Roche-partnered possibility after data let down

.One More of Ionis Pharmaceuticals' crucial midphase readouts has actually disappointed expectations...

Biogen's chief executive officer claimed no high-risk handle 2023. He prepares to be vibrant

.While Biogen's pharma peers are looking for late-stage resources with little bit of danger, chief e...

Instil refills pipeline in $2B biobucks cope with ImmunOnco

.Instil Biography has been a biotech in search of a pipe after it junked its lead properties over th...

Biogen leaves Denali Alzheimer's collab

.Biogen has actually restored rights to a very early Alzheimer's ailment system to Denali Therapeuti...

Takeda water faucets brand-new mind of US oncology business-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of considerable leadership hirings, firings and ...

Vertex, hammered by AATD once again, drops 2 assets on discard pile

.Tip's effort to alleviate an unusual genetic illness has reached another obstacle. The biotech thre...

Vir increases 3 T-cell engagers from Sanofi, lays off 25% of team

.Vir Medical's second-quarter earnings document wasn't except significant information. The business ...

Galapagos pauses CAR-T cell treatment trial over Parkinsonism instance

.Galapagos has actually stopped briefly application in a trial of a BCMA-directed CAR-T tissue thera...